[Form 4] Monopar Therapeutics Inc. Insider Trading Activity

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

4

07/16/2025 - 09:03 PM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Monopar Therapeutics Inc

NASDAQ:MNPR

MNPR Rankings

#4146 Ranked by Market Cap

N/A Ranked by Dividends

#114 Top Gainer

MNPR Latest News

Sep 3, 2025

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Aug 12, 2025

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

Jun 11, 2025

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Jun 3, 2025

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

May 13, 2025

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

MNPR Latest SEC Filings

Aug 29, 2025

[S-3] Monopar Therapeutics Inc. Shelf Registration Statement

Aug 14, 2025

[SCHEDULE 13G/A] Monopar Therapeutics Inc. SEC Filing

Aug 12, 2025

[8-K] Monopar Therapeutics Inc. Reports Material Event

Aug 12, 2025

[10-Q] Monopar Therapeutics Inc. Quarterly Earnings Report

Jul 16, 2025

[Form 4] Monopar Therapeutics Inc. Insider Trading Activity

MNPR Stock Data

Market Cap 210.70M

Float 4.06M

Insiders Ownership 34.25%

Institutions Ownership 51.77%

Short Percent 2.21%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City WILMETTE